Nec Corporation

Hitachi, Ltd.

Nippon Shinyaku Company, Ltd.

National Center of Neurology and Psychiatry

Japan Display Inc.

Hitachi Displays, Ltd.

Panasonic Liquid Crystal Display Co., Ltd.

Tokyo Medical and Dental University

Other

Nec Display Solutions, Ltd.

Seiko Instruments Inc

Hitachi Koki Co., Ltd.

Takeda Pharmaceutical Company Limited

Keio University

Hitachi Device Engineering Co., Ltd.

Tetsuya Nagata

Shin'ichi Takeda

Naoki Watanabe

Youhei Satou

Shinichi Komura

Tohru Sasaki

Takao Umeda

Tatsuo Igawa

Hideo Sato

Takahiro Ochiai

Akira Arimoto

Hirotaka Imayama

Yoshiharu Nagae

Yuji Mori

Hiroyuki Tsuzuki

Minoru Hoshino

Akio Hayasaka

Ichirou Katsuyama

Toshio Miyazawa

Shoichi Hirota

Tadao Hosaka

Osamu Itou

Takanori Yokota

Kenkichi Suzuki

Masakazu Saito

Michiko Takahashi

Koichi Fukuda

Shinji Mine

Norihiro Oura

Toshihiro Sato

Masaya Adachi

Shinichiro Oka

Isao Takahashi

Koichi Igeta

Takahiko Kato

Susumu Sasaki

Toru Miyasaka

Naoki Kato

Yasuhisa Aono

Junji Tanno

Yasuro Hori

Yasuo Takuma

Takayuki Okamoto

Hitoshi Azuma

Takuji Katsutani

Shigekazu Sasaki

Hideki Furukawa

Yuzuru Simazaki

Yoshinao Segawa

Masataka Okamoto

Tomohiro Seki

Kosuke Hidaka

Shinya Akamatsu

Takatoshi Yogo

Masao Uehara

Koji Hiraga

Shinji Nishimura

Toshiki Kaneko

Yasushi Nakano

Iwao Takemoto

Masateru Morimoto

Daisuke Sonoda

Tatsuya Sugita

Masaki Matsumori

Atsushi Hasegawa

Yoshinori Ishii

Susumu Ogawa

Yasukazu Kimura

Nobuhito Matsuyama

Tomio Yaguchi

Ryozo Takeuchi

Shigeki Nishizawa

Takahisa Yamada

Hiroshi Saito

Takeshi Furusawa

Mikiya Takeda

Hiraaki Kokame

Akio Morita

Takayuki Muranaka

Junya Kaneda

Hideyo Kodama

Tatsuo Kanetake

Shigeo Hattori

Isamu Komatsu

Toshimi Matsumoto

Yasuaki Suzuki

Sigeki Hayasaka

Genshirou Kawachi

Osamu Namikawa

Katsutoshi Saito

Takeharu Furusawa

Tomoyuki Honma

Kazuo Maruyama

Shigeki Hayasaka

Kotaro Yoshioka

Atsumu Iguchi

Mariko Jinno

Katsuyuu Takahashi

Hidekazu Nitta

Misa Iwamoto

The object of the present invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, particularly the central nervous system to which the BBB mechanism prevents drug delivery, and can produce an antisense effect on a target transcriptional product at the delivered site, and a composition comprising the same. Provided is a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, and has an antisense effect on the target transcriptional product, to a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand, and is bound to tocopherol or an analog thereof, cholesterol or an analog thereof, or a substituted or unsubstituted Calkyl group, a substituted or unsubstituted Calkenyl group, or a substituted or unsubstituted Calkoxy group.

BBB-crossing lipid ligand of hetero nucleic acid

Provided is a drug that allows highly-efficient skipping of exon. The present invention provides an antisense oligomer wherein two or more unit oligomers targeting sequences that are neither consecutive nor overlap with each other in the same exon are connected.

Antisense nucleic acids

An object of the invention is to provide a low toxicity antisense nucleic acid medicine that can modulate expression of a target transcriptional product in the central nervous system and other sites of a subject. Provided is a low toxicity composition for modulating expression of a target transcriptional product in a site such as the central nervous system of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.

Nucleic acid with reduced toxicity

Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Nucleic acid complex

The present invention provides a composition and a method for efficiently delivering a nucleic acid agent to the central nervous system and/or the retina and bringing about antisense effects. Provided is a composition for reducing the expression level of a target transcription product in the central nervous system and/or retina of a subject, the composition including a nucleic acid complex that includes a first nucleic acid strand and a second nucleic acid strand, wherein: the first nucleic acid strand comprises a base sequence capable of hybridizing with at least part of the target transcription product and has an antisense effect on the target transcription product; the second nucleic acid strand comprises a base sequence complementary to the first nucleic acid strand and is conjugated to tocopherol, cholesterol, or an analog thereof; and the first nucleic acid strand is annealed to the second nucleic acid strand.

Blood-brain barrier permeable heteroduplex nucleic acid

Provided is a drug that allows highly-efficient skipping of exon 51 in the human dystrophin gene. The present invention provides an antisense oligomer which enables exon 51 in the human dystrophin gene to be skipped.

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

A display device according to an embodiment of the present invention includes: a flexible substrate having a plurality of pixels, each of the plurality of pixels comprising a display element, the plurality of pixels being arranged in a display area; and an at least one actuator which is provided so as to fit a backside of the substrate and bends the substrate, wherein the at least one actuator is provided with a layer to shift from a flexible state to a state to have a predetermined shape and vice versa by being driven electrically, and the at least one actuator does not overlap the display element in a plan view.

Display device

A column for defining the interval between a TFT substrate and an opposed substrate is formed at a crossing point between a drain line and a scanning line. At the crossing point where the column is formed, the drain line is formed to have a wider width to prevent light leakage. Further, at the crossing point where the column is formed, the scanning line is formed to have a narrower width to prevent increase of capacitance between the drain line and the scanning line. The column is formed at a crossing point corresponding to a specific color, e.g., a blue pixel B, so that a difference in transmittance and in characteristic of thin film transistors due to formation of the column is initially compensated.

Liquid crystal display device

The present invention provides a pharmaceutical agent which causes skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene with a high efficiency. The present invention provides an oligomer which efficiently enables to cause skipping of the 55th, 45th, 50th or 44th exon in the human dystrophin gene.

Growing community of inventors

Mobara, Japan

Tetsuya Nagata